Charles Rowland's Trading History
| GBIOGeneration Bio | Feb 09, 2026 | ― | Uninformative Sell | ― | $0.00 | |
| VKTXViking Therapeutics | Jan 05, 2026 | Director | Uninformative Buy | ― | $904.33K | |
| ORTXOrchard Therapeutics | Jan 24, 2024 | ― | Uninformative Sell | ― | $0.00 | |
| NBRVFNabriva Therapeutics | Aug 03, 2022 | Director | Informative Sell | 1.44K | $237.73 | |
| BPMCBlueprint Medicines | Jun 04, 2021 | ― | Uninformative Buy | ― | $752.42K | |
| VPHMViropharma | Jan 28, 2014 | ― | Uninformative Sell | 4.35M | ― | |
| IDIXIdenix Pharma | ― | ― | ― | ― | ||
| VTAEVitae Pharma | ― | ― | ― | $0.00 | ||
| BINDQDNIB Unwind, Inc. | ― | ― | ― | $0.00 |
You May Also Like
Charles Rowland insider profile FAQ
What is the percentage of profitable transactions made by Charles Rowland?
The percentage of profitable transactions made by Charles Rowland is 46%.
What is the average return per transaction made by Charles Rowland?
The average return per transaction made by Charles Rowland is 4.70%.
What stocks does Charles Rowland hold?
Charles Rowland holds: VKTX, BINDQ, NBRVF, ORTX, GBIO, VTAE, BPMC, VPHM, IDIX stocks.
What was Charles Rowland's most profitable transaction?
Charles Rowland’s most profitable transaction was an Informative Sell of NBRVF stock on August 3, 2022. The return on the trade was 86.10%.
What is Charles Rowland's role in Viking Therapeutics?
Charles Rowland's role in Viking Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.